Objective To determine the effect of cMYBPC on the clinical phenotype of hypertrophic cardiomyopathy. Methods 226 patients with hypertrophic cardiomyopathy and 226 age- and sex-matched controls were recruited according to the diagnostic criteria of WHO. Genotyping was completed using PCR, restrictive enzyme digestion, and sequencing. Results Among three polymorphisms of MYBPC3 studied, only the GG genotype at 18443 in exon 30 was associated with the thicker left ventricular wall (25.2±5.9) mm in patient group, unlike the AA and AG genotypes (18.9±4.98) mm. After multiple regression analysis for adjustment of age and sex, the association remained. No difference was found in the genotype distribution between control and patients. Conclusions GG genotype of MYBPC3 might be a genetic risk factor for the expression of cardiac hypertrophic phenotype in patients with hypertrophic cardiomyopathy.
Key words
hypertrophic cardiomyopathy /
cMYBPC /
polymorphism
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
［1］ Bashyam M D, Savithri G R, Kumar M S, et al . Molecular genetics of familial hypertrophic cardiomyop-athy (FHC)［J］. J Hum Genet, 2003，48（11）：55–64.
［2］ Maron B J. Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations ［J］. J Am Coll Cardiol, 2001, 38（10）：315-321.
［3］ Pertti J, Johanna K, Raija M, et al . Mutations in the cardiacmyosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland［J］. J Mol Med, 2002, 80（11）：412-422.
［4］ Yang J, Liu W L, Hu D Y, et al . Novel mutations of cardiac troponin T in Chinese patients with hypertrophic cardiomyopathy ［J］，Eur J Med Genet, 2012, 11（3）：212-214.
［5］ Zhu Hu J, Xiang Li J, Hong K, et al . Hypertrophic cardiomyopathy and planned in vitro fertilization : genetic testing and clinical evaluation［J］. Herz, 2012, 15（4）：442-441.
［6］ Bos J M, Poley R N, Ny M, et al . Genotype-phenotype relationships involving hypertrophic cardiomyopathy-associated mutations in titin, muscle LIM protein, and telethonin ［J］. Mol Genet Metab, 2006 , 88(1): 78-85.
［7］ Waldmüller S, Sakthivel S, Saadi A V, et al . Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy［J］. J Mol Cell Cardiol, 2003, 35(6): 623-636.
［8］ Posch M G, Thiemann L, Tomasov P, et al . Sequence analysis of myozenin 2 in 438 European patients with familial hypertrophic cardiomyopathy［J］. Med Sci Monit, 2008, 2(5): 372-374.
［9］ Selvi Rani D, Nallari P, Dhandapany P S, et al .Cardiac troponin T (TNNT2) mutations are less prevalent in Indian hypertrophic cardiomyopathy patients［J］. DNA Cell Biol, 2011, 2(4): 145-147.
［10］ Domal-Kwiatkowska D, Smolik S, Mazurek U, et al . Genetic changes and clinical management in familial hypertrophic cardiomyopathy ［J］. Wiad Lek, 2000,1(10): 4-21.
PDF(1029 KB)
